Liquid biopsies represent a transformation in the management of cancer as they have the potential to detect, characterize, and monitor cancers earlier than conventional diagnostic modalities.

The future is plasma. There is a growing body of evidence that demonstrates how incorporating liquid biopsy-based testing into cancer clinical trials can augment traditional tissue-based testing workflows and findings.

DIA 2014 - Over the past five years a global cross-functional group (including clinical study teams, functional leaders and expert working groups) has collaborated to define and implement an enterprise RBM process.

Default

Advances in translational imaging are furthering the discovery and optimisation of tomorrow's therapeutics. Careful integration of existing imaging technologies can help to quantify the critical properties and effects of new medicines, meaning patient risk can be mitigated and benefi ts maximised.

With state-of-the-art statistical modeling and operational processes, we have the data access and tools to design and execute the most effective strategy for your clinical study.

The productivity rate of drug development continues to fall, with clinical trial efficiency a driving factor. Learn more about how adaptive clinical trials can improve both predictability and efficiency.

An interactive tool: Every stage of your product's development presents an opportunity to grow value.